A Study Examining the Medication Apremilast as Treatment for Chronic Itch

Phase 2 Completed 10 enrolled Washington University School of Medicine Celgene Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

Chronic Itch is a debilitating condition affecting many people. Currently, there are no FDA-approved treatments. Apremilast is an FDA-approved oral medication used to successfully treat the inflammatory skin disorder psoriasis and the inflammatory disorder psoriatic arthritis. This study examines if apremiliast taken twice daily relieves chronic itch.

Timeline

Start: 2017-12-01
Primary completion: 2018-10-31
Completion: 2019-09-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apremilast	Small molecule	30 mg	Oral

Indications

No indication recorded.